14-3-3 sigma increases the transcriptional activity of the androgen receptor in the absence of androgens

被引:18
作者
Quayle, Steven N. [1 ]
Sadar, Marianne D. [1 ]
机构
[1] British Columbia Canc Agcy, Michael Smith Genom Sci Ctr, Vancouver, BC V5Z 4E6, Canada
关键词
prostate cancer; 14-3-3; sigma; androgen receptor; transcriptional activator; LNCaP;
D O I
10.1016/j.canlet.2007.03.003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The androgen receptor (AR) is a ligand-activated transcription factor that regulates numerous target genes, including prostate-specific antigen (PSA). We examined the ability of each member of the 14-3-3 family to modulate transcription of PSA through the AR. Despite significant homology within the 14-3-3 family we observed differences in the ability of each isoform to alter the transcriptional activity of the AR. Significantly, 14-3-3 sigma activated PSA-luciferase reporters not only at castrate levels of androgens, but also in the complete absence of androgens. 14-3-3 sigma also increased expression of the endogenous PSA gene in the absence of androgens. Knockdown of the AR by siRNA oligonucleotides abolished activation of these reporters by 14-3-3 sigma. These findings may have greatest significance in hormone refractory prostate cancer where the AR may be activated in a ligand-independent manner. (c) 2007 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:137 / 145
页数:9
相关论文
共 40 条
[1]   Targeted proteomic analysis of 14-3-3σ, a p53 effector commonly silenced in cancer [J].
Benzinger, A ;
Muster, N ;
Koch, HB ;
Yates, JR ;
Hermeking, H .
MOLECULAR & CELLULAR PROTEOMICS, 2005, 4 (06) :785-795
[2]   The crystal structure of the non-liganded 14-3-3σ protein:: insights into determinants of isoform specific ligand binding and dimerization [J].
Benzinger, A ;
Popowicz, GM ;
Joy, JK ;
Majumdar, S ;
Holak, TA ;
Hermeking, H .
CELL RESEARCH, 2005, 15 (04) :219-227
[3]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[4]   14-3-3σ is required to prevent mitotic catastrophe after DNA damage [J].
Chan, TA ;
Hermeking, H ;
Lengauer, C ;
Kinzler, KW ;
Vogelstein, B .
NATURE, 1999, 401 (6753) :616-620
[5]   Loss of 14-3-3σ in prostate cancer and its precursors [J].
Cheng, L ;
Pan, CX ;
Zhang, JT ;
Zhang, SB ;
Kinch, MS ;
Li, L ;
Baldridge, LA ;
Wade, C ;
Hu, ZQ ;
Koch, MO ;
Ulbright, TM ;
Eble, JN .
CLINICAL CANCER RESEARCH, 2004, 10 (09) :3064-3068
[6]   An androgen response element in a far upstream enhancer region is essential for high, androgen-regulated activity of the prostate-specific antigen promoter [J].
Cleutjens, KBJM ;
vanderKorput, HAGM ;
vanEekelen, CCEM ;
vanRooij, HCJ ;
Faber, PW ;
Trapman, J .
MOLECULAR ENDOCRINOLOGY, 1997, 11 (02) :148-161
[7]   Mechanisms of endocrine therapy-responsive and -unresponsive prostate tumours [J].
Culig, Z ;
Steiner, H ;
Bartsch, G ;
Hobisch, A .
ENDOCRINE-RELATED CANCER, 2005, 12 (02) :229-244
[8]   p300 regulates androgen receptor-independent expression of prostate-specific antigen in prostate cancer cells treated chronically with interleukin-6 [J].
Debes, JD ;
Comuzzi, B ;
Schmidt, LJ ;
Dehm, SM ;
Culig, Z ;
Tindall, DJ .
CANCER RESEARCH, 2005, 65 (13) :5965-5973
[9]   Stat3 activation in prostatic carcinomas [J].
Dhir, R ;
Ni, ZY ;
Lou, W ;
DeMiguel, F ;
Grandis, JR ;
Gao, AC .
PROSTATE, 2002, 51 (04) :241-246
[10]  
Geller J, 1979, Prog Clin Biol Res, V33, P103